Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs.
Journal
Clinical and translational science
ISSN: 1752-8062
Titre abrégé: Clin Transl Sci
Pays: United States
ID NLM: 101474067
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
08
02
2022
received:
11
10
2021
accepted:
13
02
2022
pubmed:
15
4
2022
medline:
18
6
2022
entrez:
14
4
2022
Statut:
ppublish
Résumé
The accurate prediction of OATP1B-mediated drug-drug interactions (DDIs) is challenging for drug development. Here, we report a physiologically-based pharmacokinetic (PBPK) model analysis for clinical DDI data generated in heathy subjects who received oral doses of cyclosporin A (CysA; 20 and 75 mg) as an OATP1B inhibitor, and the probe drugs (pitavastatin, rosuvastatin, and valsartan). PBPK models of CysA and probe compounds were combined assuming inhibition of hepatic uptake of endogenous coproporphyrin I (CP-I) by CysA. In vivo K
Identifiants
pubmed: 35421902
doi: 10.1111/cts.13272
pmc: PMC9199885
doi:
Substances chimiques
Coproporphyrins
0
Liver-Specific Organic Anion Transporter 1
0
coproporphyrin I
531-14-6
Rosuvastatin Calcium
83MVU38M7Q
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1519-1531Informations de copyright
© 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Clin Pharmacol Ther. 2020 Apr;107(4):1004-1013
pubmed: 31628668
CPT Pharmacometrics Syst Pharmacol. 2018 Nov;7(11):739-747
pubmed: 30175555
Clin Pharmacol Ther. 2016 Nov;100(5):513-523
pubmed: 27170342
Clin Transl Sci. 2022 Jun;15(6):1519-1531
pubmed: 35421902
Drug Metab Dispos. 2020 Oct;48(10):841-848
pubmed: 32723847
J Pharmacol Exp Ther. 2005 May;313(2):549-56
pubmed: 15665139
J Pharmacokinet Biopharm. 1998 Oct;26(5):495-519
pubmed: 10205768
Clin Transl Sci. 2019 Jul;12(4):388-399
pubmed: 30982223
Pharm Res. 2013 Mar;30(3):761-80
pubmed: 23179780
Clin Pharmacol Ther. 2018 Sep;104(3):564-574
pubmed: 29243231
Clin Pharmacol Ther. 2021 Oct;110(4):1096-1105
pubmed: 34319605
Clin Pharmacol Ther. 2018 Jul;104(1):88-110
pubmed: 29315504
Drug Metab Pharmacokinet. 2019 Feb;34(1):78-86
pubmed: 30528195
Cancer Chemother Pharmacol. 2021 Sep;88(3):543-553
pubmed: 34117512
J Pharmacokinet Pharmacodyn. 2010 Dec;37(6):575-90
pubmed: 21063755
Drug Metab Dispos. 2019 Sep;47(9):966-973
pubmed: 31266752
Clin Pharmacol Ther. 2018 Nov;104(5):836-864
pubmed: 30347454
Mol Pharmacol. 1999 Dec;56(6):1219-28
pubmed: 10570049
Drug Metab Dispos. 2018 May;46(5):749-757
pubmed: 29440178
Clin Pharmacokinet. 2018 Dec;57(12):1559-1570
pubmed: 29663259
Clin Transl Sci. 2021 Jan;14(1):373-381
pubmed: 33048456
Drug Metab Dispos. 2021 Apr;49(4):298-304
pubmed: 33558262
Drug Metab Dispos. 2015 Feb;43(2):235-47
pubmed: 25414411
Bioanalysis. 2018 May 1;10(9):691-701
pubmed: 29747517
CPT Pharmacometrics Syst Pharmacol. 2021 Sep;10(9):1018-1031
pubmed: 34164937
Drug Metab Dispos. 2020 May;48(5):387-394
pubmed: 32114508
Drug Metab Dispos. 2018 Nov;46(11):1805-1816
pubmed: 30135241
Hepatology. 1999 Aug;30(2):485-90
pubmed: 10421658
Clin Pharmacol Ther. 2018 Mar;103(3):434-448
pubmed: 28560712
J Pharm Pharmacol. 1982 Nov;34(11):715-8
pubmed: 6129301
J Pharmacol Exp Ther. 2009 Feb;328(2):652-62
pubmed: 19001154
Clin Transl Sci. 2021 Jan;14(1):382-388
pubmed: 32961019
Clin Pharmacol Ther. 2020 May;107(5):1082-1115
pubmed: 31628859
Pharm Res. 2018 May 10;35(7):138
pubmed: 29748935
J Clin Pharmacol. 1987 Mar;27(3):240-2
pubmed: 3316307